195 related articles for article (PubMed ID: 37985839)
1. STAG2 Regulates Homologous Recombination Repair and Sensitivity to ATM Inhibition.
Zhou J; Nie RC; He ZP; Cai XX; Chen JW; Lin WP; Yin YX; Xiang ZC; Zhu TC; Xie JJ; Zhang YC; Wang X; Lin P; Xie D; D'Andrea AD; Cai MY
Adv Sci (Weinh); 2023 Dec; 10(36):e2302494. PubMed ID: 37985839
[TBL] [Abstract][Full Text] [Related]
2. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers.
Mondal G; Stevers M; Goode B; Ashworth A; Solomon DA
Nat Commun; 2019 Apr; 10(1):1686. PubMed ID: 30975996
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.
Bailey ML; O'Neil NJ; van Pel DM; Solomon DA; Waldman T; Hieter P
Mol Cancer Ther; 2014 Mar; 13(3):724-32. PubMed ID: 24356817
[TBL] [Abstract][Full Text] [Related]
4. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
Maeda J; Haskins JS; Kato TA
Mutat Res; 2023; 826():111815. PubMed ID: 36812659
[TBL] [Abstract][Full Text] [Related]
5. Ataxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cells.
Rass E; Chandramouly G; Zha S; Alt FW; Xie A
J Biol Chem; 2013 Mar; 288(10):7086-95. PubMed ID: 23355489
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
7. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
Peng Y; Liao Q; Tan W; Peng C; Hu Z; Chen Y; Li Z; Li J; Zhen B; Zhu W; Li X; Yao Y; Song Q; Liu C; Qi X; He F; Pei H
Nat Commun; 2019 Mar; 10(1):1224. PubMed ID: 30874560
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
9. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
10. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
12. TRIP13 regulates DNA repair pathway choice through REV7 conformational change.
Clairmont CS; Sarangi P; Ponnienselvan K; Galli LD; Csete I; Moreau L; Adelmant G; Chowdhury D; Marto JA; D'Andrea AD
Nat Cell Biol; 2020 Jan; 22(1):87-96. PubMed ID: 31915374
[TBL] [Abstract][Full Text] [Related]
13.
Mi Y; Gurumurthy RK; Zadora PK; Meyer TF; Chumduri C
mBio; 2018 Nov; 9(6):. PubMed ID: 30401777
[TBL] [Abstract][Full Text] [Related]
14. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.
Tothova Z; Valton AL; Gorelov RA; Vallurupalli M; Krill-Burger JM; Holmes A; Landers CC; Haydu JE; Malolepsza E; Hartigan C; Donahue M; Popova KD; Koochaki S; Venev SV; Rivera J; Chen E; Lage K; Schenone M; D'Andrea AD; Carr SA; Morgan EA; Dekker J; Ebert BL
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351783
[TBL] [Abstract][Full Text] [Related]
15. A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers.
Zhao K; Wang X; Xue X; Li L; Hu Y
PLoS Biol; 2020 Mar; 18(3):e3000666. PubMed ID: 32203529
[TBL] [Abstract][Full Text] [Related]
16. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
17. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
18. The dystonia gene THAP1 controls DNA double-strand break repair choice.
Shinoda K; Zong D; Callen E; Wu W; Dumitrache LC; Belinky F; Chari R; Wong N; Ishikawa M; Stanlie A; Multhaupt-Buell T; Sharma N; Ozelius L; Ehrlich M; McKinnon PJ; Nussenzweig A
Mol Cell; 2021 Jun; 81(12):2611-2624.e10. PubMed ID: 33857404
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
20. Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.
Principe DR; Narbutis M; Koch R; Rana A
Sci Rep; 2020 Nov; 10(1):20223. PubMed ID: 33214570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
